MedTrace Logo

Testosterone Replacement for Male Opioid Agonist Maintained Patients

NCT01873989 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-06-12

Study results available
· View outcomes & findings →

Summary

This study is designed to develop an effective treatment intervention for chronic pain, symptomatic hypogonadism, and opioid addiction

Conditions

Interventions

DRUG

Testosterone replacement

OTHER

Waitlist control

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Christopher J Cutter, Ph.D. · Yale University

  • Declan T Barry, Ph.D. · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01873989 on ClinicalTrials.gov